Fulltext.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(CD147) Is Induced by C/Ebpβ and Is Differentially Expressed in ALK+
Laboratory Investigation (2017) 97, 1095–1102 © 2017 USCAP, Inc All rights reserved 0023-6837/17 EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK − anaplastic large-cell lymphoma Janine Schmidt1, Irina Bonzheim1, Julia Steinhilber1, Ivonne A Montes-Mojarro1, Carlos Ortiz-Hidalgo2, Wolfram Klapper3, Falko Fend1 and Leticia Quintanilla-Martínez1 Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is characterized by expression of oncogenic ALK fusion proteins due to the translocation t(2;5)(p23;q35) or variants. Although genotypically a T-cell lymphoma, ALK+ ALCL cells frequently show loss of T-cell-specific surface antigens and expression of monocytic markers. C/EBPβ, a transcription factor constitutively overexpressed in ALK+ ALCL cells, has been shown to play an important role in the activation and differentiation of macrophages and is furthermore capable of transdifferentiating B-cell and T-cell progenitors to macrophages in vitro. To analyze the role of C/EBPβ for the unusual phenotype of ALK+ ALCL cells, C/EBPβ was knocked down by RNA interference in two ALK+ ALCL cell lines, and surface antigen expression profiles of these cell lines were generated using a Human Cell Surface Marker Screening Panel (BD Biosciences). Interesting candidate antigens were further analyzed by immunohistochemistry in primary ALCL ALK+ and ALK − cases. Antigen expression profiling revealed marked changes in the expression of the activation markers CD25, CD30, CD98, CD147, and CD227 after C/EBPβ knockdown. Immunohistochemical analysis confirmed a strong, membranous CD147 (EMMPRIN) expression in ALK+ ALCL cases. In contrast, ALK − ALCL cases showed a weaker CD147 expression. -
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only. -
Important Roles of C5a and C5ar in Tumor Development and Cancer Treatment
E3S Web o f Conferences 136, 06012 (2019) https://doi.org/10.1051/e3sconf/20191360 6012 ICBTE 2019 Important roles of C5a and C5aR in tumor development and cancer treatment Wang Yuxuan Bioengineering, School of Life Science, Anhui University,230601 Abstract: The complement system is part of the body's innate defense immune system, which can identify and eliminate invasive pathogenic microorganisms to maintain normal life activities. Complement Component 5a (C5a) is an active anaphylatoxin produced after complement system activation, closely related to tumor formation. C5a is highly expressed in a variety of tumors, and combines with its Complement Component 5a Receptor (C5aR) to increase the proliferation and migration of tumor cells. This review will comprehensively elaborate the important role of C5a/C5aR in the process of tumor genesis and development from the three aspects of signal transduction pathways related to tumor, C5a/C5aR and tumor formation, and C5a/C5aR inhibitors and tumor therapy. Finally, the principle of complement inhibition is used to inhibit tumor metastasis, reduce the rate of tumor diffusion, and control the trend of tumor deterioration. 1 Introduction The generation of tumor is closely related to the microenvironment in which tumor is located. A variety of cells in the microenvironment, such as lymphocytes, macrophages, fibroblasts and various molecules, such as complement and cytokines, are involved in the survival, proliferation and metastasis of tumor cells. Complement Component is a protein with enzyme activity. Since the discovery of complement system by Belgian doctor J. Bordet in 1890, a large number of studies have shown that complement exists in human serum, tissue fluid and cell membrane surface1. -
Shiga Toxin 2A Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines
toxins Article Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines Sára Kellnerová 1,†, Sneha Chatterjee 1,†, Rafael Bayarri-Olmos 2 , Louise Justesen 2 , Heribert Talasz 3, Wilfried Posch 1 , Samyr Kenno 1, Peter Garred 2, Dorothea Orth-Höller 1,*, Marco Grasse 1 and Reinhard Würzner 1,* 1 Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraβe 41, A-6020 Innsbruck, Austria; [email protected] (S.K.); [email protected] (S.C.); [email protected] (W.P.); [email protected] (S.K.); [email protected] (M.G.) 2 Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Rigshospitalet, University of Copenhagen, Ole Maaloesvej 26, 2200 Copenhagen, Denmark; [email protected] (R.B.-O.); [email protected] (L.J.); [email protected] (P.G.) 3 Centre of Chemistry and Biomedicine, Division of Clinical Biochemistry, Medical University of Innsbruck, Innrain 80, A-6020 Innsbruck, Austria; [email protected] * Correspondence: [email protected] (D.O.-H.); [email protected] (R.W.); Tel.: +43-512-900-370-707 (R.W.) † First authors. Abstract: Enterohemorrhagic Escherichia coli (EHEC) infections can cause EHEC-associated hemolytic uremic syndrome (eHUS) via its main virulent factor, Shiga toxins (Stxs). Complement has been reported to be involved in the progression of eHUS. The aim of this study was to investigate the interactions of the most effective subtype of the toxin, Stx2a, with pivotal complement proteins C3b and C5. -
Flow Reagents Single Color Antibodies CD Chart
CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n -
Review Article Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine
Hindawi BioMed Research International Volume 2018, Article ID 7532507, 13 pages https://doi.org/10.1155/2018/7532507 Review Article Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine Andrea Maugeri ,1 Martina Barchitta ,1 Maria Grazia Mazzone,2 Francesco Giuliano,2 and Antonella Agodi 1 1 Department of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, Via S. Sofa 87, 95123 Catania, Italy 2SIFI SpA, Research and Development Department, Via Ercole Patti 36, 95025 Catania, Italy Correspondence should be addressed to Antonella Agodi; [email protected] Received 18 May 2018; Accepted 18 July 2018; Published 26 August 2018 Academic Editor: Sajib Chakraborty Copyright © 2018 Andrea Maugeri et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Age-related macular degeneration (AMD) is the most common cause of visual loss in developed countries, with a signifcant economic and social burden on public health. Although genome-wide and gene-candidate studies have been enabled to identify genetic variants in the complement system associated with AMD pathogenesis, the efect of gene-environment interaction is still under debate. In this review we provide an overview of the role of complement system and its genetic variants in AMD, summarizing the consequences of the interaction between genetic and environmental risk factors on AMD onset, progression, and therapeutic response. Finally, we discuss the perspectives of current evidence in the feld of genomics driven personalized medicine and public health. -
High-Throughput Proteomic Profiling of the Fish Liver Following Bacterial
Causey et al. BMC Genomics (2018) 19:719 https://doi.org/10.1186/s12864-018-5092-0 RESEARCH ARTICLE Open Access High-throughput proteomic profiling of the fish liver following bacterial infection Dwight R Causey1, Moritz A N Pohl1, David A Stead2, Samuel A M Martin1, Christopher J Secombes1 and Daniel J Macqueen1* Abstract Background: High-throughput proteomics was used to determine the role of the fish liver in defense responses to bacterial infection. This was done using a rainbow trout (Oncorhynchus mykiss) model following infection with Aeromonas salmonicida, the causative agent of furunculosis. The vertebrate liver has multifaceted functions in innate immunity, metabolism, and growth; we hypothesize this tissue serves a dual role in supporting host defense in parallel to metabolic adjustments that promote effectiveimmunefunction.Whilepaststudieshavereported mRNA responses to A. salmonicida in salmonids, the impact of bacterial infection on the liver proteome remains uncharacterized in fish. Results: Rainbow trout were injected with A. salmonicida or PBS (control) and liver extracted 48 h later for analysis on a hybrid quadrupole-Orbitrap mass spectrometer. A label-free method was used for protein abundance profiling, which revealed a strong innate immune response along with evidence to support parallel rewiring of metabolic and growth systems. 3076 proteins were initially identified against all proteins (n = 71,293 RefSeq proteins) annotated in a single high-quality rainbow trout reference genome, of which 2433 were maintained for analysis post-quality filtering. Among the 2433 proteins, 109 showed significant differential abundance following A. salmonicida challenge, including many upregulated complement system and acute phase response proteins, in addition to molecules with putative functions that may support metabolic re-adjustments. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
No Evidence for Basigin/CD147 As a Direct SARS-Cov-2 Spike
www.nature.com/scientificreports OPEN No evidence for basigin/CD147 as a direct SARS‑CoV‑2 spike binding receptor Jarrod Shilts 1*, Thomas W. M. Crozier 2, Edward J. D. Greenwood2, Paul J. Lehner 2 & Gavin J. Wright 1,3* The spike protein of SARS‑CoV‑2 is known to enable viral invasion into human cells through direct binding to host receptors including ACE2. An alternate entry receptor for the virus was recently proposed to be basigin/CD147. These early studies have already prompted a clinical trial and multiple published hypotheses speculating on the role of this host receptor in viral infection and pathogenesis. Here, we report that we are unable to fnd evidence supporting the role of basigin as a putative spike binding receptor. Recombinant forms of the SARS‑CoV‑2 spike do not interact with basigin expressed on the surface of human cells, and by using specialized assays tailored to detect receptor interactions as weak or weaker than the proposed basigin‑spike binding, we report no evidence for a direct interaction between the viral spike protein to either of the two common isoforms of basigin. Finally, removing basigin from the surface of human lung epithelial cells by CRISPR/Cas9 results in no change in their susceptibility to SARS‑CoV‑2 infection. Given the pressing need for clarity on which viral targets may lead to promising therapeutics, we present these fndings to allow more informed decisions about the translational relevance of this putative mechanism in the race to understand and treat COVID‑19. Te sudden emergence of SARS-CoV-2 in late 2019 has demanded extensive research be directed to resolve the many uncharted aspects of this previously-unknown virus. -
Complement and Inflammasome Overactivation Mediates Paroxysmal Nocturnal Hemoglobinuria with Autoinflammation
Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation Britta Höchsmann, … , Peter M. Krawitz, Taroh Kinoshita J Clin Invest. 2019. https://doi.org/10.1172/JCI123501. Research Article Hematology Inflammation Graphical abstract Find the latest version: https://jci.me/123501/pdf The Journal of Clinical Investigation RESEARCH ARTICLE Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation Britta Höchsmann,1,2 Yoshiko Murakami,3,4 Makiko Osato,3,5 Alexej Knaus,6 Michi Kawamoto,7 Norimitsu Inoue,8 Tetsuya Hirata,3 Shogo Murata,3,9 Markus Anliker,1 Thomas Eggermann,10 Marten Jäger,11 Ricarda Floettmann,11 Alexander Höllein,12 Sho Murase,7 Yasutaka Ueda,5 Jun-ichi Nishimura,5 Yuzuru Kanakura,5 Nobuo Kohara,7 Hubert Schrezenmeier,1 Peter M. Krawitz,6 and Taroh Kinoshita3,4 1Institute of Transfusion Medicine, University of Ulm, Ulm, Germany. 2Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm, Germany. 3Research Institute for Microbial Diseases and 4WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. 5Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan. 6Institute for Genomic Statistics and Bioinformatics, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 7Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan. 8Department of Tumor Immunology, Osaka -
Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................ -
International Union of Basic and Clinical Pharmacology. LXXXVII
Supplemental Material can be found at: /content/suppl/2014/09/18/65.1.500.DC1.html 1521-0081/65/1/500–543$25.00 http://dx.doi.org/10.1124/pr.111.005223 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:500–543, January 2013 Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors Andreas Klos, Elisabeth Wende, Kathryn J. Wareham, and Peter N. Monk Department for Medical Microbiology, Medical School Hannover, Hannover, Germany (A.K., E.W.); and the Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, United Kingdom (K.J.W., P.N.M.) Abstract. ....................................................................................502 I. Introduction. ..............................................................................503 A. Production of Complement Peptides......................................................503 B. Concentrations of Complement Peptides in Health and Disease. .........................503 C. C3a and C5a Generation outside the Complement Cascade ...............................504 D. Deactivation of Complement Peptides ....................................................505 II. The Role of Complement Peptides in Pathophysiology . .....................................505 A. Complement Peptides Are Important Biomarkers of Disease..............................505 B. Functions of the Complement Peptides beyond Innate Immunity .........................506